Decitabine
From Wikipedia, the free encyclopedia
| Image:Decitabine.gif | |
|
Decitabine
|
|
| Systematic (IUPAC) name | |
| 4-amino-1-(2-deoxy-b-D-erythro-pentofuranosyl)
-1,3,5-triazin-2(1H)-one |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C8H12N4O4 |
| Mol. mass | 228.0859 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | <1% |
| Metabolism | ? |
| Half life | 30 minutes |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
D |
| Legal status | |
| Routes | intravenously |
Decitabine (Dacogen®), or 5-aza-2'-deoxy-cytidine, is indicated for treatment of patients with myelodysplastic syndrome (MDS), including previously treated and untreated, de novo, and secondary MDS of all FAB subtypes and Intermediate-1, Intermediate-2, and High-Risk IPSS groups. It functions in the same way as 5-Azacytidine.
[edit] Basic Information
- Trade Name: Dacogen®
- Generic Name: decitabine
- FDA approved: May 2, 2006
- Classification: demethylating agent
- Manufacturer: MGI Pharma
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
